Quick Answer
Co-Diagnostics, Inc. reported Stockholders Equity of $20.63 million for fiscal year 2025.
Co-Diagnostics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $20.63M | -61.7% |
| 2024 | $53.88M | -37.0% |
| 2023 | $85.58M | -25.3% |
| 2022 | $114.52M | -14.8% |
| 2021 | $134.48M | +101.6% |
| 2020 | $66.70M | +3739.2% |
| 2019 | $1.74M | +264.1% |
| 2018 | -$1.06M | -127.5% |
| 2017 | $3.85M | +228.6% |
| 2016 | -$2.99M | -161.0% |
| 2015 | -$1.15M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $39.83M | -37.6% | -3.2% |
| June 30, 2025 | $41.14M | -43.2% | -14.2% |
| March 31, 2025 | $47.92M | -38.8% | -11.8% |
| December 31, 2024 | $54.31M | -36.9% | -14.9% |
| September 30, 2024 | $63.78M | -35.9% | -11.9% |
| June 30, 2024 | $72.40M | -30.0% | -7.6% |
| March 31, 2024 | $78.35M | -29.2% | -8.9% |
| December 31, 2023 | $86.01M | -24.9% | -13.5% |
- Co-Diagnostics, Inc. showed a decrease of -61.7% in Stockholders Equity compared to the prior fiscal year.
- Over the 2015–2025 period, Co-Diagnostics, Inc.’s stockholders equity has grown by 1897.9% (from -$1.15 million to $20.63 million).
- The most recent figure is from Co-Diagnostics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: